Royalty Pharma 

$28.7
269
-$0.37-1.27% Friday 20:00

統計

當日最高
29.12
當日最低
28.61
52週最高
31.66
52週最低
25.2
成交量
1,821,599
平均成交量
2,654,988
市值
17.23B
市盈率
19.35
股息收益率
2.93%
股息
0.84

即將到來

股息

2.93%股息收益率
10年增長
N/A
5年增長率
N/A
3年增長率
7.3%
1年增長率
5%

收益

6Nov預期
Q1 2023
Q2 2023
Q3 2023
Q4 2023
Q1 2024
Q2 2024
下一個
0.77
1.05
1.32
1.6
預期每股收益
0.918884
實際每股收益
N/A

人們還關注

此列表基於在 Stock Events 上關注 RPRX 的人的關注列表。這不是投資建議。

競爭者

這個列表是基於最近市場事件的分析。這不是投資建議。

分析師評級

42$平均價格目標
最高估價為 $51。
來自過去 6 個月內的 4 個評級。這不是投資建議。
買入
75%
持有
25%
賣出
0%

關於

Health Technology
Pharmaceuticals: Major
Manufacturing
Medicinal and Botanical Manufacturing
Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies. Its portfolio consists of royalties on approximately 35 marketed therapies and 10 development-stage product candidates that address various therapeutic areas, such as rare disease, cancer, neurology, infectious disease, hematology, and diabetes. The company was founded in 1996 and is based in New York, New York.
Show more...
首席執行官
Pablo Gerardo Legorreta
員工
75
國家
GB
ISIN
GB00BMVP7Y09

上市公司